Today’s Short Interest: Biolinerx Limited Ads (NASDAQ:BLRX) Can’t Be Less Risky. Short Interest Decreased

November 28, 2016 - By Louis Casey   ·   0 Comments

Today's Short Interest: Biolinerx Limited Ads (NASDAQ:BLRX) Can't Be Less Risky. Short Interest Decreased

The stock of Biolinerx Limited Ads (NASDAQ:BLRX) registered a decrease of 1.76% in short interest. BLRX’s total short interest was 173,100 shares in November as published by FINRA. Its down 1.76% from 176,200 shares, reported previously. With 94,700 shares average volume, it will take short sellers 2 days to cover their BLRX’s short positions. The short interest to Biolinerx Limited Ads’s float is 0.39%. The stock increased 4.60% or $0.05 on November 25, hitting $1.09. Bioline RX Ltd (NASDAQ:BLRX) has risen 10.20% since April 25, 2016 and is uptrending. It has outperformed by 4.19% the S&P500.

BioLine RX Ltd is an Israel-based company engaged in the development of therapeutics, from preclinical-stage development to advanced clinical trials, for a range of medical needs. The company has a market cap of $61.59 million. The Company’s clinical therapeutic candidates under development consist of BL-1020 that is in Phase II/III clinical trials to improve cognitive function in schizophrenia patients; BL-1040, which is under pivotal CE-Mark registration trial for the prevention of cardiac remodeling following an acute myocardial infarction; BL-5010, which has completed Phase I/II clinical trials for non-surgical removal of skin lesions; BL-1021 that has completed Phase Ia clinical trial for the treatment of neuropathic pain or pain that results from damage to nerve fibers, and BL-7040, a synthetic oligonucleotide, which is in Phase II clinical trial for the treatment of inflammatory bowel disease. It currently has negative earnings.

Bioline RX Ltd (NASDAQ:BLRX) Ratings Coverage

Out of 3 analysts covering BioLineRx (NASDAQ:BLRX), 2 rate it a “Buy”, 0 “Sell”, while 1 “Hold”. This means 67% are positive. $7 is the highest target while $3 is the lowest. The $5 average target is 358.72% above today’s ($1.09) stock price. BioLineRx has been the topic of 3 analyst reports since July 27, 2015 according to StockzIntelligence Inc. The stock has “Hold” rating given by Maxim Group on Friday, August 12. The stock of Bioline RX Ltd (NASDAQ:BLRX) has “Market Outperform” rating given on Wednesday, March 9 by JMP Securities. The stock of Bioline RX Ltd (NASDAQ:BLRX) earned “Buy” rating by TH Capital on Monday, July 27.

More notable recent Bioline RX Ltd (NASDAQ:BLRX) news were published by: Prnewswire.com which released: “BioLineRx Reports Third Quarter 2016 Financial Results” on November 22, 2016, also Prnewswire.com with their article: “BioLineRx and I-Bridge Capital Establish a New Drug Development Joint Venture …” published on August 25, 2016, Marketwatch.com published: “BioLine RX stock price target cut to $1 from $4 at Maxim Group” on June 02, 2011. More interesting news about Bioline RX Ltd (NASDAQ:BLRX) were released by: Streetinsider.com and their article: “BioLineRx (BLRX) Enters In-Licensing Agreement for Anti-Inflammatory DES Treatment” published on November 21, 2016 as well as Prnewswire.com‘s news article titled: “BioLineRx to Report Third Quarter Results on November 22, 2016” with publication date: November 15, 2016.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By Louis Casey


Readers Comments (0)





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>